- Home
- DOYU vs TRDA Comparison
DOYU vs TRDA Comparison
Compare DOYU & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOYU
- TRDA
- Stock Information
- Founded
- DOYU 2014
- TRDA 2016
- Country
- DOYU China
- TRDA United States
- Employees
- DOYU N/A
- TRDA N/A
- Industry
- DOYU Computer Software: Programming Data Processing
- TRDA Biotechnology: Pharmaceutical Preparations
- Sector
- DOYU Technology
- TRDA Health Care
- Exchange
- DOYU Nasdaq
- TRDA Nasdaq
- Market Cap
- DOYU 246.3M
- TRDA 220.1M
- IPO Year
- DOYU 2019
- TRDA 2021
- Fundamental
- Price
- DOYU $8.28
- TRDA $6.14
- Analyst Decision
- DOYU Hold
- TRDA Strong Buy
- Analyst Count
- DOYU 1
- TRDA 3
- Target Price
- DOYU $7.00
- TRDA $25.67
- AVG Volume (30 Days)
- DOYU 78.3K
- TRDA 276.7K
- Earning Date
- DOYU 08-18-2025
- TRDA 08-06-2025
- Dividend Yield
- DOYU 238.73%
- TRDA N/A
- EPS Growth
- DOYU N/A
- TRDA N/A
- EPS
- DOYU N/A
- TRDA N/A
- Revenue
- DOYU $586,290,301.00
- TRDA $79,476,000.00
- Revenue This Year
- DOYU N/A
- TRDA N/A
- Revenue Next Year
- DOYU N/A
- TRDA N/A
- P/E Ratio
- DOYU N/A
- TRDA N/A
- Revenue Growth
- DOYU N/A
- TRDA N/A
- 52 Week Low
- DOYU $5.68
- TRDA $4.93
- 52 Week High
- DOYU $19.30
- TRDA $21.79
- Technical
- Relative Strength Index (RSI)
- DOYU 57.64
- TRDA 54.29
- Support Level
- DOYU $7.90
- TRDA $5.23
- Resistance Level
- DOYU $8.59
- TRDA $5.47
- Average True Range (ATR)
- DOYU 0.43
- TRDA 0.41
- MACD
- DOYU 0.04
- TRDA 0.11
- Stochastic Oscillator
- DOYU 76.43
- TRDA 90.30
About DOYU DouYu International Holdings Limited ADS
DouYu International Holdings Ltd is a game-centric live streaming platform in China and a pioneer in the eSports value chain. The company operates its platform on both PC and mobile apps, through which users can enjoy immersive and interactive games and entertainment live streaming. It generates revenues through live streaming and advertisement.
About TRDA Entrada Therapeutics Inc.
Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.